COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.01
+1.66%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -28.5%
- EBIT
- -29.8%
- EPS
- +4.5%
- Free cash flow
- -31.8%
- Operating cash flow
- -31.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +23.7%
- EPS
- +26.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -27.7%
- EBIT
- -20.8%
- Net income
- -28.6%
- EPS
- +12.1%
- Free cash flow
- -27.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026